A short report on NGM282/aldafermin for the treatment of nonalcoholic steatohepatitis (NASH)

References

• Younossi ZM, Anstee, QM, and Marietti, M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11–20.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Koenig, AB, and Abdelatif, D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84.
   PubMed Web of Science ®Google Scholar
• Araujo A, Rosso, N, and Bedogni, G, et al. Global epidemiology of non-alcoholic fatty liver disease/ non-alcoholic steatohepatitis: what we need in the future. Liver Int. 2018;38(Suppplement 1):47–51.
   PubMedGoogle Scholar
• Younossi ZM, Stepanova M, Ong J, et al. Nonalcoholic Steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States. Clin Gastroenterol Hepatol. 2021;19(3):580–589.e5.
   PubMed Web of Science ®Google Scholar
• Wong V, Chan W, Chitturi S, et al. Asia–Pacific working party on non-alcoholic fatty liver disease guidelines 2017— part 1: definition, risk factors and assessment. J Gastroenterol Hepatol. 2018;33:70–85.
   PubMed Web of Science ®Google Scholar
• Singh S, Allen A, Wang Z, et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13:643–54 e1–9.
   Web of Science ®Google Scholar
• Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34(3):274–285.
   PubMed Web of Science ®Google Scholar
• Dulai P, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017;65:1557–1565.
   PubMed Web of Science ®Google Scholar
• Williams C, Stengel J, Asike M, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140:124–131.
   PubMed Web of Science ®Google Scholar
• Argo C, Caldwell S. Epidemiology and natural history of non-alcoholic steatohepatitis. Clin Liver Dis. 2009;13:511–531.
   PubMed Web of Science ®Google Scholar
• Brunt E, Kleiner D, Wilson L, et al. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology. 2009;49:809–820.
   PubMed Web of Science ®Google Scholar
• Kleiner D, Brunt E, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–1321.
   PubMed Web of Science ®Google Scholar
• Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology. 2012;142:711–725.
   PubMed Web of Science ®Google Scholar
• Tsochatzis E, Papatheodoridis G, Archimandritis A. Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy. Mediators Inflamm. 2009;2009:831670.
   PubMed Web of Science ®Google Scholar
• Yamada K, Mizukoshi E, Sunagozaka H, et al. Characteristics of hepatic fatty acid composition in patients with nonalcoholic steatohepatitis. Liver Int. 2014;35:582–590.
   PubMed Web of Science ®Google Scholar
• Kliewer S, Mangelsdorf D. Bile acids as hormones: the FXR-FGF15/19 pathway. Dig Dis. 2015;33:327–331.
   PubMed Web of Science ®Google Scholar
• Arab J, Karpen S, Dawson P, et al. Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives. Hepatology. 2017;65:350–362.
   PubMed Web of Science ®Google Scholar
• Allen K, Jaeschke H, Copple B. Bile acids induce inflammatory genes in hepatocytes: a novel mechanism of inflammation during obstructive cholestasis. Am J Pathol. 2011;178: 175–18.
   Web of Science ®Google Scholar
• Adachi T, Kaminaga T, Yasuda H, et al. The involvement of endoplasmic reticulum stress in bile acid-induced hepatocellular injury. J Clin Biochem Nutr. 2014;54:129–135.
   PubMed Web of Science ®Google Scholar
• Sokol R, Straka M, Dahl R, et al. Role of oxidant stress in the permeability transition induced in rat hepatic mitochondria by hydrophobicbile acids. Pediatr Res. 2001;49:519–531.
   PubMed Web of Science ®Google Scholar
• Svegliati-Baroni G, Ridolfi F, Hannivoort R, et al. Bile acids induce hepatic stellatecell proliferation via activation of the epidermal growth factor receptor. Gastroenterology. 2005;128:1042–1055.
   PubMed Web of Science ®Google Scholar
• Kharitonenkov A, Shanafelt A. FGF21: a novel prospect for the treatment of metabolic diseases. Curr Opin Invest Drugs. 2009;10:359–364.
   PubMedGoogle Scholar
• Degirolamo C, Sabba C, Moschetta A. Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. Nat Rev Drug Discov. 2016;15:51–69.
   PubMed Web of Science ®Google Scholar
• Kir S, Beddow S, Samuel V, et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science. 2011;331:1621–1624.
   PubMed Web of Science ®Google Scholar
• Potthoff M, Boney-Montoya J, Choi M, et al. FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB- PGC-1α pathway. Cell Metab. 2011;13:729–738.
   PubMed Web of Science ®Google Scholar
• Jahn D, Rau M, Hermanns H, et al. Mechanisms of enterohepatic fibroblast growth factor 15/19 signaling in health and disease. Cytokine Growth Factor Rev. 2015;26:625–635.
   PubMed Web of Science ®Google Scholar
• Zhou M, Wang X, Phung V, et al. Separating tumorigenicity from bile acid regulatory activity for endocrine hormone FGF19. Cancer Res. 2014;74:3306–3316.
   PubMed Web of Science ®Google Scholar
• Luo J, Ko B, Elliott M, et al. A nontumorigenic variant of FGF19 treats cholestatic liver disease. Sci Transl Med. 2014;6:247ra100.
   PubMed Web of Science ®Google Scholar
• DePaoli A, Zhou M, Kaplan D, et al. FGF19 analog as a surgical factor mimetic that contributes to metabolic effects beyond glucose homeostasis. Diabetes. 2019;68(6):1315–1328.
   PubMed Web of Science ®Google Scholar
• Zhou M, Yang H, Learned RM, et al. Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis. Nat Commun. 2017;8:15433.
   PubMed Web of Science ®Google Scholar
• Tomlinson E, Fu L, John L, et al. Transgenic mice expressing human fibroblast growthfactor-19 display increased metabolic rate and decreased adiposity. Endocrinology. 2002;143:1741–1747.
   PubMed Web of Science ®Google Scholar
• Fu L, John L, Adams S, et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin- deficient diabetes. Endocrinology. 2004;145:2594–2603.
   PubMed Web of Science ®Google Scholar
• Alvarez-Sola G, Uriarte I, Latasa M, et al. Fibroblast growth factor 15/19 (FGF15/19) protects from diet-induced hepatic steatosis:development of an FGF19-based chimeric molecule to promote fatty liver regeneration. Gut. 2017;66:1818–1828.
   PubMed Web of Science ®Google Scholar
• Nicholes K, Guillet S, Tomlinson E, et al. A mouse model of hepatocellular carcinoma:ectopic expression of fibroblast growth factor 19 in skeletal mus-cle of transgenic mice. Am J Pathol. 2002;160:2295–2307.
   PubMed Web of Science ®Google Scholar
• Zhou M, Learned R, and Rossi SJ, et al. Engineered FGF19 eliminates bile acid toxicity and lipotoxicity leading to resolution of steatohepatitis and fibrosis in mice. Hepatol Commun. 2017; 1:1024–1042.
   PubMed Web of Science ®Google Scholar
• Luo J, Ko B, To C, et al. Treatment with NGM282 significantly improves liver histopathology in a mouse model of non- alcoholic steatohepatitis (NASH). J Hepatol. 2015;62(Suppl. 2):S694.
   Google Scholar
• Ling L, Zhou M, Yang H, et al. NGM282 exhibits potent anti-inflammatory and antifibrotic activity in FXR-null mice with non-alcoholic steatohepatitis (NASH) histopathology. J Hepatol. 2015;62(Suppl. 2):S694–S695.
   Google Scholar
• Harrison SA, Rinella ME, Abdelmalak MF, et al. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2018;391:1174–1185.
   PubMed Web of Science ®Google Scholar
• Harrison SA, Rossi SJ, Paredes AH, et al. NGM282 improves liver fibrosis and histology in 12 weeks in patients with nonalcoholic steatohepatitis. Hepatology. 2020;71:1198–2012.
   PubMed Web of Science ®Google Scholar
• Harrison SA, Neff G, Guy CD, et al. Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis. Gastroenterology. 2021;160(1):219–231.
   PubMed Web of Science ®Google Scholar
• Ornitz DM, Itoh N. Fibroblast growth factors. Genome Biol. 2001;2(3):S3005.
   Web of Science ®Google Scholar
• Daphna-Iken D, Shankar DB, Lawshe A, et al. MMTV-Fgf8 transgenic mice develop mammary and salivary gland neoplasia and ovarian stromal hyperplasia. Oncogene. 1998;17(21):2711–2717.
   PubMed Web of Science ®Google Scholar
• Clark JC, Tichelaar JW, Wert SE, et al. FGF-10 disrupts lung morphogenesis and causes pulmonary adenomas in vivo. Am J Physiol Lung Cell Mol Physiol. 2001;280(4):L705–15.
   PubMed Web of Science ®Google Scholar
• French DM, Lin BC, Wang M, et al. Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models. PLoS One. 2012;7(5):e36713.
   PubMed Web of Science ®Google Scholar
• Pai R, Dunlap D, Qing J, et al. Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating beta-catenin signaling. Cancer Res. 2008;68(13):5086–5095.
   PubMed Web of Science ®Google Scholar
• Drenth JPH, Schattenberg JM. The nonalcoholic steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future success. Expert Opin Investig Drugs. 2020;29(12):1365–1375.
   PubMed Web of Science ®Google Scholar
• Ratziu V. Non-pharmacological interventions in non-alcoholic fatty liver disease patients. Liver Int. 2017;37(Suppl 1):90–96.
   PubMedGoogle Scholar
• Smith GI, Shankaran M, Yoshino M, et al. Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease. J Clin Invest. 2020;130(3):1453–1460.
   PubMed Web of Science ®Google Scholar
• Chow MD, Lee YH, Guo GL. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Mol Aspects Med. 2017;56:34–44.
   PubMed Web of Science ®Google Scholar
• Chiang JYL. Bile acid metabolism and signaling in liver disease and therapy. Liver Res. 2017 Jun;1(1):3–9.
   PubMedGoogle Scholar
• Services USDoHaH, Administration FaD, (CDER) CfDEaR. Noncirrhotic nonalcoholic steatohepatitis with liver fibrosis: developing drugs for treatment guidance for Indust. Accessed 2021 July 3. https://www.fda.gov/media/119044/download
   Google Scholar
• Sanyal AJ, Brunt EM, Kleiner DE, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology. 2011;54(1):344–353.
   PubMedGoogle Scholar